ACIU - AC Immune Ltd
AC Immune Ltd Logo

ACIU - AC Immune Ltd

https://www.acimmune.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.

52W High
$3.98
52W Low
$1.43
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.61
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
11.24
EV/EBITDA (<8 favorable)
-0.76
EV/Revenue (<3 favorable)
2.43
P/S (TTM) (<3 favorable)
8.35
P/B (<3 favorable)
2.56
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
38.01%
Institutions (25–75% balanced)
24.72%
Shares Outstanding
100,600,000
Float
39,960,700
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
28,918,000
Gross Profit (TTM)
-34,091,000
EPS (TTM)
-0.63
Profit Margin (>10% good)
-1.75%
Operating Margin (TTM) (higher better)
-14.85%
ROE (TTM) (>15% strong)
-0.51%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.90
Momentum
Bearish momentum
Value
0.0744
Previous
0.0590
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025